
Teriparatide, sold under the brand name Forteo among others, is a form of parathyroid hormone (PTH) consisting of the first (N-terminus) 34 amino acids, which is the portion of the hormone activating the Parathyroid hormone 1 receptor. It is an effective anabolic (promoting bone formation) agent used in the treatment of some forms of osteoporosis. Teriparatide is a recombinant human parathyroid hormone analog (PTH 1-34). It has an identical sequence to the 34 N-terminal amino acids of the 84-amino acid human parathyroid hormone.
Teriparatide is indicated for the treatment of postmenopausal women with osteoporosis; for the increase of bone mass in men with primary or hypogonadal osteoporosis; and treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.
It is effective in growing bone (e.g., 8% increase in bone density in the spine after one year) and reducing the risk of fragility fractures.
Teriparatide cuts the risk of hip fracture by more than half but does not reduce the risk of arm or wrist fracture.
Teriparatide is contraindicated for those with open epiphyses, metabolic bone diseases, Paget's Disease of bone, bone metastases, history of skeletal malignancies, or prior external beam or implant radiation therapy involving the skeleton. In the animal studies and in one human case report, it was found to potentially be associated with developing osteosarcoma in test subjects after over two years of use.
×